JP2002515758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002515758A5 JP2002515758A5 JP1998535951A JP53595198A JP2002515758A5 JP 2002515758 A5 JP2002515758 A5 JP 2002515758A5 JP 1998535951 A JP1998535951 A JP 1998535951A JP 53595198 A JP53595198 A JP 53595198A JP 2002515758 A5 JP2002515758 A5 JP 2002515758A5
- Authority
- JP
- Japan
- Prior art keywords
- powder
- cells
- nutrient medium
- media
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims description 313
- 210000004027 cell Anatomy 0.000 claims description 277
- 239000002609 medium Substances 0.000 claims description 264
- 238000000034 method Methods 0.000 claims description 216
- 235000015097 nutrients Nutrition 0.000 claims description 179
- 210000002966 serum Anatomy 0.000 claims description 160
- 239000000872 buffer Substances 0.000 claims description 151
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 115
- 239000012577 media supplement Substances 0.000 claims description 91
- 239000012913 medium supplement Substances 0.000 claims description 91
- 239000007788 liquid Substances 0.000 claims description 86
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 78
- 239000000306 component Substances 0.000 claims description 58
- 239000006143 cell culture medium Substances 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 51
- 238000001694 spray drying Methods 0.000 claims description 49
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 39
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 37
- 239000013589 supplement Substances 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 34
- 210000004102 animal cell Anatomy 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 25
- 238000004113 cell culture Methods 0.000 claims description 25
- 102000004338 Transferrin Human genes 0.000 claims description 23
- 108090000901 Transferrin Proteins 0.000 claims description 23
- 239000012581 transferrin Substances 0.000 claims description 23
- 238000004659 sterilization and disinfection Methods 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 244000309466 calf Species 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 15
- 238000010979 pH adjustment Methods 0.000 claims description 15
- 239000012888 bovine serum Substances 0.000 claims description 14
- 239000000337 buffer salt Substances 0.000 claims description 14
- 238000004806 packaging method and process Methods 0.000 claims description 14
- 210000005253 yeast cell Anatomy 0.000 claims description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229930182816 L-glutamine Natural products 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000006285 cell suspension Substances 0.000 claims description 10
- 239000012894 fetal calf serum Substances 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 210000004907 gland Anatomy 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 210000003501 vero cell Anatomy 0.000 claims description 9
- 230000000087 stabilizing effect Effects 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 7
- 230000004931 aggregating effect Effects 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 239000002858 neurotransmitter agent Substances 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 241000244206 Nematoda Species 0.000 claims description 5
- 239000007975 buffered saline Substances 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 210000002308 embryonic cell Anatomy 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 239000012092 media component Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical group 0.000 claims description 5
- 210000001082 somatic cell Anatomy 0.000 claims description 5
- 150000003408 sphingolipids Chemical class 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 239000002953 phosphate buffered saline Substances 0.000 claims description 4
- 230000001817 pituitary effect Effects 0.000 claims description 4
- 239000003656 tris buffered saline Substances 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 108010007093 dispase Proteins 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 239000012533 medium component Substances 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 239000006193 liquid solution Substances 0.000 claims 2
- 210000001557 animal structure Anatomy 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000000647 trehalose group Chemical group 0.000 claims 1
- 239000012091 fetal bovine serum Substances 0.000 description 102
- 239000000203 mixture Substances 0.000 description 84
- 239000001963 growth medium Substances 0.000 description 77
- 238000009472 formulation Methods 0.000 description 62
- 230000002776 aggregation Effects 0.000 description 44
- 239000007921 spray Substances 0.000 description 31
- 238000004220 aggregation Methods 0.000 description 30
- 230000008569 process Effects 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 28
- 230000012010 growth Effects 0.000 description 27
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 26
- 241000196324 Embryophyta Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 238000001035 drying Methods 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 21
- 239000012530 fluid Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000005054 agglomeration Methods 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 14
- -1 media subgroups Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000010261 cell growth Effects 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000012124 Opti-MEM Substances 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 239000000428 dust Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000000498 ball milling Methods 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000003139 buffering effect Effects 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 229940047122 interleukins Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 229940047120 colony stimulating factors Drugs 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 239000012570 Opti-MEM I medium Substances 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 241000256248 Spodoptera Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 210000001361 achilles tendon Anatomy 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 239000003855 balanced salt solution Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000002338 cryopreservative effect Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000006153 eosin methylene blue Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229960002413 ferric citrate Drugs 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 108010045676 holotransferrin Proteins 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 239000012194 insect media Substances 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- ORRBHGDXBDFSFM-UHFFFAOYSA-N 1h-indole;nitric acid Chemical compound O[N+]([O-])=O.C1=CC=C2NC=CC2=C1 ORRBHGDXBDFSFM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000007755 F10 Nutrient Mixture Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006451 grace's insect medium Substances 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4031497P | 1997-02-14 | 1997-02-14 | |
| US60/040,314 | 1997-02-14 | ||
| US5871697P | 1997-09-12 | 1997-09-12 | |
| US60/058,716 | 1997-09-12 | ||
| US6219297P | 1997-10-16 | 1997-10-16 | |
| US60/062,192 | 1997-10-16 | ||
| PCT/US1998/002829 WO1998036051A1 (en) | 1997-02-14 | 1998-02-17 | Dry powder cells and cell culture reagents and methods of production thereof |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004311607A Division JP2005118046A (ja) | 1997-02-14 | 2004-10-26 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2007035545A Division JP2007125044A (ja) | 1997-02-14 | 2007-02-15 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2010141177A Division JP2010233580A (ja) | 1997-02-14 | 2010-06-22 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002515758A JP2002515758A (ja) | 2002-05-28 |
| JP2002515758A5 true JP2002515758A5 (cg-RX-API-DMAC7.html) | 2010-08-12 |
| JP4557311B2 JP4557311B2 (ja) | 2010-10-06 |
Family
ID=27365699
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53595198A Expired - Lifetime JP4557311B2 (ja) | 1997-02-14 | 1998-02-17 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2004311607A Withdrawn JP2005118046A (ja) | 1997-02-14 | 2004-10-26 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2007035545A Withdrawn JP2007125044A (ja) | 1997-02-14 | 2007-02-15 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2007275837A Withdrawn JP2008043343A (ja) | 1997-02-14 | 2007-10-24 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2009058864A Withdrawn JP2009118864A (ja) | 1997-02-14 | 2009-03-12 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2010141177A Pending JP2010233580A (ja) | 1997-02-14 | 2010-06-22 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2013266253A Expired - Lifetime JP5985463B2 (ja) | 1997-02-14 | 2013-12-25 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2016110896A Pending JP2016152821A (ja) | 1997-02-14 | 2016-06-02 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004311607A Withdrawn JP2005118046A (ja) | 1997-02-14 | 2004-10-26 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2007035545A Withdrawn JP2007125044A (ja) | 1997-02-14 | 2007-02-15 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2007275837A Withdrawn JP2008043343A (ja) | 1997-02-14 | 2007-10-24 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2009058864A Withdrawn JP2009118864A (ja) | 1997-02-14 | 2009-03-12 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2010141177A Pending JP2010233580A (ja) | 1997-02-14 | 2010-06-22 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2013266253A Expired - Lifetime JP5985463B2 (ja) | 1997-02-14 | 2013-12-25 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
| JP2016110896A Pending JP2016152821A (ja) | 1997-02-14 | 2016-06-02 | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US6383810B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2186882B1 (cg-RX-API-DMAC7.html) |
| JP (8) | JP4557311B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE507283T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU6654998A (cg-RX-API-DMAC7.html) |
| CA (2) | CA2798535C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69842243D1 (cg-RX-API-DMAC7.html) |
| DK (3) | DK1702978T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2516790T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998036051A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040067157A1 (en) * | 1993-07-22 | 2004-04-08 | Clearant, Inc. | Methods for sterilizing biological materials |
| US5362442A (en) * | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| EP0891419A4 (en) * | 1996-03-12 | 2000-03-01 | Life Technologies Inc | NUTRIENT ADDITIVE FOR HEMATOPOETIC CELL CULTURES |
| US20030203036A1 (en) * | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| EP1005529B1 (en) | 1997-02-12 | 2005-04-27 | Invitrogen Corporation | Methods for lyophilizing competent cells |
| US6383810B2 (en) * | 1997-02-14 | 2002-05-07 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
| US20060003447A1 (en) * | 2003-12-30 | 2006-01-05 | Richard Fike | Dry powder cells and cell culture reagents and methods of production thereof |
| US20060003448A1 (en) * | 2003-12-30 | 2006-01-05 | Richard Fike | Dry powder cells and cell culture reagents and methods of production thereof |
| EP1091765A4 (en) * | 1998-06-30 | 2001-10-24 | Invitrogen Corp | Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby |
| AU6021699A (en) * | 1998-09-01 | 2000-03-21 | Penn State Research Foundation | Method and apparatus for aseptic growth or processing of biomass |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| FR2804326B1 (fr) * | 2000-01-27 | 2002-10-18 | Ellipse Pharmaceuticals | Procede de sterilisation par traitement sous hautes pressions de principes actifs sensibles |
| EP1762251A1 (en) * | 2000-03-23 | 2007-03-14 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20040086420A1 (en) * | 2000-03-23 | 2004-05-06 | Macphee Martin J. | Methods for sterilizing serum or plasma |
| IL136232A0 (en) * | 2000-05-18 | 2001-05-20 | Bar Ilan University Res Author | Measurements of enzymatic activity in a single, individual cell in population |
| US7575761B2 (en) * | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
| WO2002009669A2 (en) * | 2000-08-01 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Apparatus and process to produce particles having a narrow size distribution and particles made thereby |
| KR100385713B1 (ko) * | 2000-08-30 | 2003-05-27 | 사회복지법인삼성생명공익재단(삼성서울병원) | 면역병리 염색용 완충액 |
| AU2002232406C1 (en) * | 2000-11-06 | 2009-03-05 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
| ATE356870T1 (de) * | 2000-12-21 | 2007-04-15 | Merck Patent Gmbh | Verfahren zur herstellung von kompetenten oder transformierten zellen |
| US20020114795A1 (en) | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US6682695B2 (en) * | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
| US6696060B2 (en) * | 2001-06-14 | 2004-02-24 | Clearant, Inc. | Methods for sterilizing preparations of monoclonal immunoglobulins |
| US20030031584A1 (en) * | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
| US6946098B2 (en) | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
| US6749851B2 (en) * | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| AU2002331847A1 (en) * | 2001-09-14 | 2003-04-01 | Invitrogen Corporation | Composition for stabilizing biological materials |
| US6783968B2 (en) * | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
| US20030095890A1 (en) * | 2001-09-24 | 2003-05-22 | Shirley Miekka | Methods for sterilizing biological materials containing non-aqueous solvents |
| US20030185702A1 (en) * | 2002-02-01 | 2003-10-02 | Wilson Burgess | Methods for sterilizing tissue |
| US20110091353A1 (en) * | 2001-09-24 | 2011-04-21 | Wilson Burgess | Methods for Sterilizing Tissue |
| EP1438385A1 (en) * | 2001-10-25 | 2004-07-21 | Bar-Ilan University | Interactive transparent individual cells biochip processor |
| EP1992335A1 (en) * | 2001-11-01 | 2008-11-19 | Nektar Therapeutics | Spray drying methods and compositions thereof |
| EP2251417A1 (en) * | 2001-11-30 | 2010-11-17 | Life Technologies Corporation | Dry powder cell culture medium containing liquid and methods of production thereof |
| US20030124023A1 (en) * | 2001-12-21 | 2003-07-03 | Wilson Burgess | Method of sterilizing heart valves |
| US20030180181A1 (en) * | 2002-02-01 | 2003-09-25 | Teri Greib | Methods for sterilizing tissue |
| GB0216562D0 (en) * | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| US6908591B2 (en) * | 2002-07-18 | 2005-06-21 | Clearant, Inc. | Methods for sterilizing biological materials by irradiation over a temperature gradient |
| DE10234165B4 (de) * | 2002-07-26 | 2008-01-03 | Advanced Micro Devices, Inc., Sunnyvale | Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material |
| KR20050088243A (ko) | 2002-12-30 | 2005-09-02 | 넥타르 테라퓨틱스 | 프리필름화 분무기 |
| US7033612B2 (en) * | 2003-01-03 | 2006-04-25 | Kang David S | Composition and method for treating age-related disorders |
| IL154677A0 (en) * | 2003-02-27 | 2003-09-17 | Univ Bar Ilan | A method and apparatus for manipulating an individual cell |
| AU2004236740A1 (en) * | 2003-05-02 | 2004-11-18 | Sigma-Aldrich Co. | Solid phase cell lysis and capture platform |
| US20060240548A1 (en) * | 2003-06-26 | 2006-10-26 | Mordechai Deutsch | Materials for constructing cell-chips, cell-chip covers, cell-chips coats, processed cell-chips and uses thereof |
| US7888110B2 (en) | 2003-06-26 | 2011-02-15 | Seng Enterprises Ltd. | Pico liter well holding device and method of making the same |
| US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
| US8597597B2 (en) * | 2003-06-26 | 2013-12-03 | Seng Enterprises Ltd. | Picoliter well holding device and method of making the same |
| WO2005008626A1 (en) * | 2003-07-11 | 2005-01-27 | University Of North Carolina At Chapel Hill | Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop |
| US20050064524A1 (en) * | 2003-08-11 | 2005-03-24 | Mordechai Deutsch | Population of cells utilizable for substance detection and methods and devices using same |
| WO2005074893A1 (en) * | 2004-02-03 | 2005-08-18 | Chemagis Ltd. | Stable amorphous forms of montelukast sodium |
| WO2006003664A1 (en) * | 2004-07-07 | 2006-01-12 | Seng Enterprises Ltd. | Method and device for identifying an image of a well in an image of a well-bearing component |
| US7403647B2 (en) * | 2004-09-13 | 2008-07-22 | Seng Enterprises Ltd. | Method for identifying an image of a well in an image of a well-bearing component |
| WO2006026248A1 (en) * | 2004-08-25 | 2006-03-09 | Sigma-Aldrich Co. | Compositions and methods employing zwitterionic detergent combinations |
| US20080009051A1 (en) * | 2004-08-25 | 2008-01-10 | Seng Enterprises Ltd. | Method and Device for Isolating Cells |
| ES2352344T3 (es) | 2005-01-25 | 2011-02-17 | Seng Enterprises Limited | Dispositivo de microfluido para estudio de células. |
| DE102005034043B4 (de) * | 2005-07-18 | 2019-12-12 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch |
| US20070141555A1 (en) * | 2005-10-11 | 2007-06-21 | Mordechai Deutsch | Current damper for the study of cells |
| WO2007052245A1 (en) * | 2005-11-03 | 2007-05-10 | Seng Enterprises Ltd. | Method and device for studying floating, living cells |
| US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
| US7718616B2 (en) | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| US9145540B1 (en) | 2007-11-15 | 2015-09-29 | Seng Enterprises Ltd. | Device for the study of living cells |
| WO2009081409A2 (en) | 2007-12-26 | 2009-07-02 | Seng Enterprises Ltd. | Device for the study of living cells |
| BRPI1006722A2 (pt) * | 2009-04-09 | 2017-10-10 | Entegrion Inc | "método de preparação de hemoderivados desidratado, hemoderivados desidratados, bandagem ou auxílio cirúrgico, método para a preparação de plaquetas sanguíneas fixas desidratadas, plaquetas sanguíneas fixas desidratadas, método para o tratamento de um paciente que sofre de um distúrbio sanguíneo e plaquetas de sangue fixas secas por atomização tendo geometria com cavidades esféricas" |
| JP2013528175A (ja) * | 2010-05-28 | 2013-07-08 | ガーネット バイオセラピューティクス インコーポレイテッド | インビトロで培養し、増殖させた自己複製コロニー形成細胞由来の成分を有する、生存しているおよび生存していない生理活性デバイスの組成物ならびにそれらの使用法 |
| WO2012068135A1 (en) | 2010-11-15 | 2012-05-24 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| EP2652123B1 (en) | 2010-12-16 | 2016-01-13 | Merck Patent GmbH | Dry granulated cell culture media |
| KR102007997B1 (ko) | 2011-02-07 | 2019-08-07 | 라이프 테크놀로지스 코포레이션 | 감수성 화합물을 안정화시키는 조성물 및 방법 |
| US9481861B2 (en) * | 2011-07-12 | 2016-11-01 | Foodchek Systems, Inc. | Culture medium, method for culturing Salmonella and E. coli and method for detecting Salmonella and E. coli |
| JP6216327B2 (ja) | 2011-12-22 | 2017-10-18 | ライフ テクノロジーズ コーポレーション | 細胞培地および方法 |
| EP2674482A1 (en) * | 2012-06-15 | 2013-12-18 | Merck Patent GmbH | Process for producing cell culture media |
| EP2877569B1 (en) | 2012-07-25 | 2017-11-15 | 3M Innovative Properties Company | Agglomerated microbiological media |
| EP2882842B1 (en) * | 2012-08-07 | 2019-02-20 | 3M Innovative Properties Company | Method of making agglomerated microbiological media and compositions thereof |
| ES2856937T3 (es) * | 2013-07-11 | 2021-09-28 | Merck Patent Gmbh | Medios de cultivo celular |
| KR20180049193A (ko) | 2014-02-21 | 2018-05-10 | 라이프 테크놀로지스 코포레이션 | 배지 재수화 시스템, 방법 및 장치 |
| CA2945390A1 (en) | 2014-04-10 | 2015-10-15 | Bayer Healthcare Llc | Compounded media powder formulation and method of preparation of liquid medium for cell culture |
| US12227760B2 (en) | 2014-07-07 | 2025-02-18 | Ambrothia, Llc | Wet granulated cell culture medium and preparation method therefor |
| KR101617858B1 (ko) * | 2014-07-07 | 2016-05-04 | 유한책임회사 암브로티아 | 습식 과립화된 세포 배양 배지 및 그 제조방법 |
| WO2016085787A1 (en) | 2014-11-25 | 2016-06-02 | Corning Incorporated | Cell culture media extending materials and methods |
| CN107849527A (zh) * | 2015-08-05 | 2018-03-27 | 默克专利股份公司 | 生产细胞培养基的方法 |
| US10822584B2 (en) | 2015-12-17 | 2020-11-03 | Life Technologies Corporation | Pellets used in cell culture and methods of making thereof |
| CN108699510A (zh) * | 2015-12-30 | 2018-10-23 | 生命技术公司 | 细胞培养用层状颗粒及其制法 |
| MX389076B (es) * | 2016-06-24 | 2025-03-19 | Agbiome Inc | Métodos y composiciones para secar por rociado bacterias gram-negativas. |
| EP3491121A1 (en) | 2016-07-28 | 2019-06-05 | Merck Patent GmbH | Process for improving the dissolution behaviour of components in aqueous solutions |
| US20200008299A1 (en) * | 2016-10-21 | 2020-01-02 | Bao Tran | Flexible printed electronics |
| EP3875595A4 (en) * | 2018-11-02 | 2022-07-13 | Kyowa Kirin Co., Ltd. | Liquid medium preparation method |
| EP4031648A1 (en) | 2019-09-19 | 2022-07-27 | Life Technologies Corporation | Cell culture media tablets and methods of manufacture |
| CN114641562B (zh) | 2019-11-14 | 2025-07-08 | 默克专利股份公司 | 细胞培养基 |
| US20230022796A1 (en) | 2019-12-19 | 2023-01-26 | Merck Patent Gmbh | Methods and compositions for modulating the glycosylation profile of proteins |
| US20210395698A1 (en) | 2020-06-22 | 2021-12-23 | Life Technologies Corporation | Methods and compositions for cultivating pluripotent cell suspensions |
| WO2022084386A1 (en) | 2020-10-21 | 2022-04-28 | Merck Patent Gmbh | Poloxamers for cell culture |
| DK4261274T3 (da) | 2022-04-13 | 2025-06-23 | Merck Patent Gmbh | Meroxapoler til cellekultur |
| KR20250143775A (ko) | 2023-02-07 | 2025-10-02 | 라이프 테크놀로지스 코포레이션 | 실온 안정성 배양 배지 및 보충제 |
| WO2024170622A1 (en) | 2023-02-16 | 2024-08-22 | Merck Patent Gmbh | Cell culture media |
| CN116576654B (zh) * | 2023-04-27 | 2025-12-26 | 中国天辰工程有限公司 | 一种闭式循环小苏打气流干燥器系统及使用方法 |
| MX2023006528A (es) * | 2023-06-01 | 2025-01-09 | Raul Francisco Moedano Lara | Proceso para la obtencion de un cristalizado de suero fetal bovino con agmatina |
| WO2025096837A1 (en) | 2023-10-31 | 2025-05-08 | Life Technologies Corporation | Freeze-dried cell culture media and supplements |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1355192U (cg-RX-API-DMAC7.html) | ||||
| US2835586A (en) | 1953-07-27 | 1958-05-20 | Instant Milk Company | Dried milk product and method of making same |
| NL6601640A (cg-RX-API-DMAC7.html) * | 1965-02-11 | 1966-08-12 | ||
| DE1949690A1 (de) | 1969-10-02 | 1971-04-08 | Egon Laumen | Behaelter,insbesondere Milchbeutel,aus Kunststoffolie |
| DK123067B (da) * | 1970-09-25 | 1972-05-15 | Niro Atomizer As | Fremgangsmåde til behandling af et pulverformigt, fedtholdigt mælkeprodukt. |
| GB1355192A (en) * | 1970-12-21 | 1974-06-05 | Niro Atomizer As | Methods for producing agglomerated coffee powder and other powders and apparatus for carrying out the method |
| DK125813B (da) | 1971-04-16 | 1973-05-07 | Niro Atomizer As | Apparat til tørring af fugtige pulvere. |
| US4072570A (en) * | 1972-04-11 | 1978-02-07 | Beatrice Foods Co. | Preparation of a tuberculosis test medium by reconstituting a storage stabilized dry powdered Lowenstein-Jensen medium |
| CS169007B1 (cg-RX-API-DMAC7.html) | 1973-05-18 | 1976-06-29 | ||
| US4073951A (en) * | 1974-04-18 | 1978-02-14 | Sargeant Ralph G | Agglomeration method |
| IL44853A (en) | 1974-05-17 | 1975-11-25 | Isorad Isotopes & Radiation | Process for the preparation of sterile culture media and culture medium thus obtained |
| US3920857A (en) * | 1974-10-21 | 1975-11-18 | Central Soya Co | Method of preparing a granular free-flowing lecithin product |
| JPS5652542B2 (cg-RX-API-DMAC7.html) | 1975-02-24 | 1981-12-12 | ||
| DD119304A1 (cg-RX-API-DMAC7.html) | 1975-04-23 | 1976-04-12 | ||
| US4053542A (en) | 1976-07-22 | 1977-10-11 | Acf Industries, Inc. | Control means for secondary throttle |
| US4282326A (en) * | 1978-10-12 | 1981-08-04 | Jeanne Moldenhauer | Cell culture medium supplement |
| US4241186A (en) * | 1978-12-18 | 1980-12-23 | Conviron, Inc. | Pectin culture media and method |
| US4615978A (en) | 1979-06-28 | 1986-10-07 | The State Of Oregon, By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Bacterial growth medium and method of use |
| US4282255A (en) * | 1979-06-28 | 1981-08-04 | State Of Oregon, By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Method and starter compositions for the growth of acid producing bacteria and bacterial compositions produced thereby |
| DE3171242D1 (en) | 1980-10-06 | 1985-08-08 | Chlorella Industry Co | Cell culture method |
| JPS57152882A (en) | 1981-03-14 | 1982-09-21 | Kikujiro Ishiwatari | Method for killing living general chlorella |
| JPS57206398A (en) | 1981-06-15 | 1982-12-17 | Eiken Kagaku Kk | Dried culture medium for identifying cell |
| US4416898A (en) * | 1982-03-01 | 1983-11-22 | Pharmuka Laboratoires | Therapeutic uses of methionine |
| JPH07105474B2 (ja) | 1983-09-28 | 1995-11-13 | 株式会社日立製作所 | 半導体メモリ |
| US4511592A (en) | 1982-03-11 | 1985-04-16 | Scm Corporation | Preparation of acidulated meat emulsions |
| DK157053B (da) * | 1982-06-14 | 1989-11-06 | Niro Atomizer As | Fremgangsmaade til fremstilling af et agglomereret, pulverformet maelkeprodukt |
| US4544637A (en) | 1982-09-14 | 1985-10-01 | Igi Biotechnology, Inc. | Culture media from clarified diary whey lactose permeates |
| DD228951A3 (de) * | 1982-12-02 | 1985-10-23 | Inst Getreideverarbeitung | Verfahren zur herstellung von granulierter nahrung |
| US4511593A (en) * | 1983-01-17 | 1985-04-16 | Multi-Arc Vacuum Systems Inc. | Vapor deposition apparatus and method |
| SU1097253A1 (ru) | 1983-02-25 | 1984-06-15 | Опытное Конструкторско-Технологическое Бюро По Интенсификации Тепломассообменных Процессов | Способ получени сухого ацидофильного препарата |
| JPS59501933A (ja) | 1983-03-02 | 1984-11-22 | アイジ−アイ、バイオテクノロジ−、インコ−ポレイテッド | 清澄化した酪産乳漿ラクト−ス透過物を培地および他の商業的に有用な製品への転換 |
| US4621058A (en) | 1983-04-11 | 1986-11-04 | Mid-America Dairymen, Inc. | Method of preparing cheese starter media |
| US4673649A (en) | 1983-07-15 | 1987-06-16 | University Patents, Inc. | Process and defined medium for growth of human epidermal keratinocyte cells |
| US4620908A (en) | 1983-10-03 | 1986-11-04 | Biocell Laboratories, Inc. | Method for destroying microbial contamination in protein materials |
| FR2559499B1 (fr) | 1984-02-09 | 1986-09-19 | Hoechst Behring Applic Pharmac | Nouveau milieu de culture, solide, a delitement rapide, pret a l'emploi et procede pour le preparer |
| US4689297A (en) | 1985-03-05 | 1987-08-25 | Miles Laboratories, Inc. | Dust free particulate enzyme formulation |
| US4632980A (en) * | 1985-04-03 | 1986-12-30 | Immunologics | Ozone decontamination of blood and blood products |
| US4975246A (en) | 1985-09-30 | 1990-12-04 | Charm Stanley E | High temperature, short time heating system and method of heating heat-sensitive material |
| US4820627A (en) * | 1986-03-24 | 1989-04-11 | Em Diagnostic Systems, Inc. | Method of preparing particles suitable for tabletting into diagnostic reagents |
| GB8620003D0 (en) | 1986-08-16 | 1986-09-24 | Arbuthnoit R D | Accessory device |
| JPH067791B2 (ja) | 1986-12-12 | 1994-02-02 | 農薬バイオテクノロジ−開発技術研究組合 | オ−トクレ−ブ滅菌無血清培地による昆虫細胞の培養法 |
| GB8700354D0 (en) | 1987-01-08 | 1987-02-11 | Distillers Co | Culture of micro-organisms |
| DE3871206D1 (de) | 1987-03-24 | 1992-06-25 | Grace W R & Co | Basisnaehrmedium fuer eine zellkultur. |
| DK158532C (da) | 1987-07-14 | 1990-10-29 | Niro Atomizer As | Toerreapparat, der arbejder med fluid bed, og lejeplade dertil |
| US4848122A (en) * | 1987-07-20 | 1989-07-18 | Chemtronics | Method and apparatus for deburring using shot |
| GB8718756D0 (en) * | 1987-08-07 | 1987-09-16 | Unilever Plc | Supporting means |
| JPH0646941B2 (ja) * | 1987-12-11 | 1994-06-22 | サントール株式会社 | 微生物の培養法 |
| GB8800572D0 (en) | 1988-01-12 | 1988-02-10 | Red Baron Oil Tools Rental | Improvements in/relating to drilling tool |
| US5006204A (en) | 1988-08-10 | 1991-04-09 | A/S Niro Atomizer | Apparatus for crystallizing whey |
| JPH0257175A (ja) * | 1988-08-19 | 1990-02-26 | Morinaga & Co Ltd | 成形培地及びその製造法 |
| NO901662L (no) * | 1989-04-17 | 1990-12-21 | Monsanto Co | Toert herbicid preparat med forbedret vannopploeselighet. |
| EP0441092A1 (en) | 1990-02-08 | 1991-08-14 | Niro Holding A/S | A method and apparatus for heat treating a particulate product |
| US5254073A (en) * | 1990-04-27 | 1993-10-19 | Kapak Corporation | Method of making a vented pouch |
| ES2067007T3 (es) | 1990-09-11 | 1995-03-16 | Niro Holding As | Metodo y aparato para el tratamiento con gas de un material o producto pulverulento o en particulas. |
| JPH0761259B2 (ja) | 1990-10-08 | 1995-07-05 | 工業技術院長 | 酵母細胞内物質の抽出法 |
| JPH04198137A (ja) | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | 無菌乾燥炭酸ナトリウムの製法 |
| JP2895641B2 (ja) * | 1991-02-28 | 1999-05-24 | ハウス食品株式会社 | 動物細胞増殖促進剤及びそれを用いた動物細胞増殖方法 |
| US5700426A (en) | 1991-03-08 | 1997-12-23 | Foundation Nationale De Transfusion Sanguine | Method for decontaminating or sterilizing "in situ" a vacuum sealed container and device for implementing such method |
| DK0507038T3 (da) | 1991-04-05 | 1994-10-17 | Niro Holding As | Apparat med fluidiserende leje og fremgangsmåde til fremstilling af samme |
| GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| DE544887T1 (de) * | 1991-06-17 | 1994-02-03 | Life Technologies Inc | Technik zur konzentration von kulturmedien. |
| US5155039A (en) | 1991-07-22 | 1992-10-13 | Chrisope Technologies, Inc. | Apparatus for methods for preserving, transporting storing, re-hydrating and delivering viable micro-organisms |
| US5445792A (en) * | 1992-03-13 | 1995-08-29 | American Sterilizer Company | Optimum hydrogen peroxide vapor sterlization method |
| US5325606A (en) | 1992-12-23 | 1994-07-05 | Niro A/S | Process and apparatus for drying and calcining sodium bicarbonate |
| US5366696A (en) | 1993-01-07 | 1994-11-22 | 1077075 Ontario Inc. | Oxygenation apparatus for oxygenating a carrier liquid by spraying |
| WO1994027645A1 (en) * | 1993-05-28 | 1994-12-08 | Porton International Plc | System for packaging and delivering of a sterile powder medium |
| WO1994028746A1 (en) | 1993-06-15 | 1994-12-22 | Commonwealth Scientific And Industrial Research Organisation | Improved fumigation of particulate commodities |
| DK75293D0 (da) * | 1993-06-24 | 1993-06-24 | Anhydro As | Fremgangsmaade og anlaeg til et agglomereret produkt |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| DK62994A (da) * | 1993-11-15 | 1995-05-16 | Niro Holding As | Apparat og fremgangsmåde til fremstilling af et agglomereret materiale |
| AU5623194A (en) | 1993-11-15 | 1995-06-06 | Niro Holding A/S | Fluid bed for producing and/or processing a particulate material |
| US5563068A (en) * | 1994-04-21 | 1996-10-08 | Genetic Therapy, Inc. | Bioreactor |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US5662897A (en) * | 1994-07-27 | 1997-09-02 | U. Of Ga Research Foundation | Insect viruses, sequences, insecticidal compositions and methods of use |
| US5733774A (en) * | 1995-02-02 | 1998-03-31 | Ecoscience Corporation | Method and composition for producing stable bacteria and bacterial formulations |
| US5811406A (en) | 1995-06-07 | 1998-09-22 | Regents Of The University Of California | Dry powder formulations of polynucleotide complexes |
| EP0857201A1 (en) * | 1995-09-18 | 1998-08-12 | Minnesota Mining And Manufacturing Company | Thin film culture plate device containing granulated medium particles |
| DE19535581C1 (de) * | 1995-09-25 | 1996-10-31 | Cpc Maizena Gmbh | Verfahren zur Herstellung von Eierstich |
| JP4421681B2 (ja) | 1995-10-19 | 2010-02-24 | バイオ‐オリジン エルエルシー | 生殖細胞および胚の生存および機能を改善する方法および組成物 |
| SE507856C2 (sv) | 1996-04-12 | 1998-07-20 | Acanova Ab | Värmesanering av fröer |
| US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
| WO1998015297A1 (en) | 1996-10-09 | 1998-04-16 | Lifetech Corporation | Method for the sterilization of biological materials |
| US5773279A (en) | 1996-11-27 | 1998-06-30 | Neogen Corporation | Culture medium and method for repair of microbial cells |
| GB9625175D0 (en) | 1996-12-04 | 1997-01-22 | Medi Cult As | Serum-free cell culture media |
| US20060003448A1 (en) * | 2003-12-30 | 2006-01-05 | Richard Fike | Dry powder cells and cell culture reagents and methods of production thereof |
| US6383810B2 (en) * | 1997-02-14 | 2002-05-07 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
| US20060003447A1 (en) * | 2003-12-30 | 2006-01-05 | Richard Fike | Dry powder cells and cell culture reagents and methods of production thereof |
| US6627426B2 (en) | 1997-02-14 | 2003-09-30 | Invitrogen Corporation | Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby |
| US20040022666A1 (en) * | 1998-06-30 | 2004-02-05 | Invitrogen Corporation | Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby |
| US6210715B1 (en) * | 1997-04-01 | 2001-04-03 | Cap Biotechnology, Inc. | Calcium phosphate microcarriers and microspheres |
| US6045838A (en) * | 1998-08-10 | 2000-04-04 | Davis; Harold L. | Grape handling and storage bag |
| JP4144677B2 (ja) | 1999-02-24 | 2008-09-03 | 日本開閉器工業株式会社 | 傾斜スイッチ |
| US6206571B1 (en) | 1999-06-24 | 2001-03-27 | Alan D. Olin | Flexible bag with resealable pour spout |
| AU2002232406C1 (en) * | 2000-11-06 | 2009-03-05 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
| EP2251417A1 (en) * | 2001-11-30 | 2010-11-17 | Life Technologies Corporation | Dry powder cell culture medium containing liquid and methods of production thereof |
-
1998
- 1998-02-13 US US09/023,790 patent/US6383810B2/en not_active Expired - Lifetime
- 1998-02-17 AT AT06002712T patent/ATE507283T1/de not_active IP Right Cessation
- 1998-02-17 DK DK06002712.5T patent/DK1702978T3/da active
- 1998-02-17 EP EP09180261.1A patent/EP2186882B1/en not_active Expired - Lifetime
- 1998-02-17 AU AU66549/98A patent/AU6654998A/en not_active Abandoned
- 1998-02-17 CA CA2798535A patent/CA2798535C/en not_active Expired - Lifetime
- 1998-02-17 EP EP10175914.0A patent/EP2281873B1/en not_active Expired - Lifetime
- 1998-02-17 CA CA2280741A patent/CA2280741C/en not_active Expired - Lifetime
- 1998-02-17 JP JP53595198A patent/JP4557311B2/ja not_active Expired - Lifetime
- 1998-02-17 WO PCT/US1998/002829 patent/WO1998036051A1/en not_active Ceased
- 1998-02-17 DK DK09180261.1T patent/DK2186882T3/en active
- 1998-02-17 DK DK10175914.0T patent/DK2281873T3/da active
- 1998-02-17 EP EP98908542A patent/EP1012234A4/en not_active Withdrawn
- 1998-02-17 ES ES10175914.0T patent/ES2516790T3/es not_active Expired - Lifetime
- 1998-02-17 EP EP06002712A patent/EP1702978B1/en not_active Expired - Lifetime
- 1998-02-17 DE DE69842243T patent/DE69842243D1/de not_active Expired - Lifetime
-
2003
- 2003-10-16 US US10/685,802 patent/US7572632B2/en not_active Expired - Fee Related
-
2004
- 2004-10-26 JP JP2004311607A patent/JP2005118046A/ja not_active Withdrawn
-
2007
- 2007-02-15 JP JP2007035545A patent/JP2007125044A/ja not_active Withdrawn
- 2007-10-24 JP JP2007275837A patent/JP2008043343A/ja not_active Withdrawn
-
2009
- 2009-03-12 JP JP2009058864A patent/JP2009118864A/ja not_active Withdrawn
-
2010
- 2010-06-22 JP JP2010141177A patent/JP2010233580A/ja active Pending
-
2012
- 2012-04-20 US US13/452,498 patent/US20120276630A1/en not_active Abandoned
- 2012-09-11 US US13/610,370 patent/US20130065300A1/en not_active Abandoned
-
2013
- 2013-12-25 JP JP2013266253A patent/JP5985463B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-02 JP JP2016110896A patent/JP2016152821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5985463B2 (ja) | 乾燥粉末細胞および細胞培養試薬ならびにこれらの生成方法 | |
| JP6166744B2 (ja) | 乾燥粉末細胞および細胞培養試薬およびその生産の方法 | |
| AU2002232406A1 (en) | Dry powder cells and cell culture reagents and methods of production thereof | |
| JP2010000088A (ja) | 脂質を含む粉末細胞培養製品およびその製造法 | |
| JP2011087593A (ja) | 外来性因子および毒素を減弱するための方法ならびにそれにより産生される細胞培養試薬。 | |
| US20060003448A1 (en) | Dry powder cells and cell culture reagents and methods of production thereof | |
| JP2002519009A (ja) | 外来性因子および毒素を減弱するための方法ならびにそれにより産生される細胞培養試薬。 |